Evolus (NASDAQ:EOLS) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Evolus (NASDAQ:EOLS) from a hold rating to a buy rating in a research note issued to investors on Thursday morning, ValuEngine reports.

A number of other research analysts have also recently commented on EOLS. Barclays reiterated a hold rating on shares of Bank of Montreal in a report on Tuesday, June 11th. Mizuho set a $31.00 price objective on Evolus and gave the stock a buy rating in a research report on Monday, May 20th. SunTrust Banks upped their price objective on Smartsheet to $56.00 and gave the stock a positive rating in a research report on Wednesday, March 20th. They noted that the move was a valuation call. Zacks Investment Research lowered EXACT Sciences from a hold rating to a sell rating in a research report on Tuesday, July 2nd. Finally, Wells Fargo & Co assumed coverage on Establishment Labs in a research report on Friday, June 28th. They set an outperform rating and a $29.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Evolus has a consensus rating of Buy and a consensus target price of $26.67.

Shares of Evolus stock opened at $19.00 on Thursday. The firm has a market cap of $519.33 million, a PE ratio of -12.10 and a beta of 4.82. The business’s 50 day moving average is $14.73. Evolus has a 1-year low of $10.22 and a 1-year high of $30.25. The company has a current ratio of 14.80, a quick ratio of 14.52 and a debt-to-equity ratio of 0.96.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Tuesday, April 30th. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.11). As a group, research analysts forecast that Evolus will post -2.92 earnings per share for the current fiscal year.

In other Evolus news, major shareholder Corp Alphaeon sold 5,307,940 shares of the company’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $19.25, for a total value of $102,177,845.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Simone Blank acquired 628,536 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was bought at an average price of $19.25 per share, with a total value of $12,099,318.00. The disclosure for this purchase can be found here. Insiders acquired 1,931,327 shares of company stock valued at $37,157,482 in the last 90 days.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Patriot Financial Group Insurance Agency LLC boosted its stake in Evolus by 50.0% in the first quarter. Patriot Financial Group Insurance Agency LLC now owns 1,500 shares of the company’s stock valued at $34,000 after acquiring an additional 500 shares in the last quarter. Meeder Asset Management Inc. boosted its stake in shares of Evolus by 48.9% during the first quarter. Meeder Asset Management Inc. now owns 1,732 shares of the company’s stock worth $39,000 after buying an additional 569 shares during the period. Pearl River Capital LLC boosted its stake in shares of Evolus by 217.7% during the first quarter. Pearl River Capital LLC now owns 1,906 shares of the company’s stock worth $44,000 after buying an additional 1,306 shares during the period. BNP Paribas Arbitrage SA boosted its stake in shares of Evolus by 8,877.3% during the first quarter. BNP Paribas Arbitrage SA now owns 1,975 shares of the company’s stock worth $45,000 after buying an additional 1,953 shares during the period. Finally, Edge Wealth Management LLC acquired a new stake in shares of Evolus during the second quarter worth about $29,000. Institutional investors own 14.43% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: What is the NASDAQ Stock Market?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.